High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study

Leuk Lymphoma. 2008 Jun;49(6):1202-5. doi: 10.1080/10428190802094237.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Doxorubicin / administration & dosage
  • Equilibrative Nucleoside Transporter 1 / metabolism*
  • Female
  • Gemcitabine
  • Hodgkin Disease / metabolism*
  • Hodgkin Disease / pathology
  • Hodgkin Disease / therapy
  • Humans
  • Liposomes
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy*
  • Reed-Sternberg Cells / metabolism*
  • Survival Rate
  • Treatment Failure
  • Vinblastine / administration & dosage
  • Vinblastine / analogs & derivatives
  • Vinorelbine

Substances

  • Equilibrative Nucleoside Transporter 1
  • Liposomes
  • SLC29A1 protein, human
  • Deoxycytidine
  • Vinblastine
  • Doxorubicin
  • Vinorelbine
  • Gemcitabine